Log in

Relevant bibliographies by topics / VMAT2 Inhibitor / Journal articles

To see the other types of publications on this topic, follow the link: VMAT2 Inhibitor.

Journal articles on the topic 'VMAT2 Inhibitor'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'VMAT2 Inhibitor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Meyer, Jonathan M., Craig Chepke, Rimal B. Bera, et al. "Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review." Mental Health Clinician 13, no. 5 (2023): 225–32. http://dx.doi.org/10.9740/mhc.2023.10.225.

Full text

Abstract:

Abstract Introduction Two vesicular monoamine transporter 2 (VMAT2) inhibitors are approved in the United States (US) for the treatment of tardive dyskinesia (TD). There is a paucity of information on the impact of VMAT2 inhibitor treatment on patient social and physical well-being. The study objective was to elucidate clinician-reported improvement in symptoms and any noticeable changes in social or physical well-being in patients receiving VMAT2 inhibitors. Methods A web-based survey was offered to physicians, nurse practitioners, and physician assistants based in the US who prescribed valbe

APA, Harvard, Vancouver, ISO, and other styles

2

Yaffe, Dana, Ariela Vergara-Jaque, Lucy R. Forrest, and Shimon Schuldiner. "Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis." Proceedings of the National Academy of Sciences 113, no. 47 (2016): E7390—E7398. http://dx.doi.org/10.1073/pnas.1605162113.

Full text

Abstract:

Neurotransporters located in synaptic vesicles are essential for communication between nerve cells in a process mediated by neurotransmitters. Vesicular monoamine transporter (VMAT), a member of the largest superfamily of transporters, mediates transport of monoamines to synaptic vesicles and storage organelles in a process that involves exchange of two H+ per substrate. VMAT transport is inhibited by the competitive inhibitor reserpine, a second-line agent to treat hypertension, and by the noncompetitive inhibitor tetrabenazine, presently in use for symptomatic treatment of hyperkinetic disor

APA, Harvard, Vancouver, ISO, and other styles

3

Peckham, Alyssa M., and Jessica A. Nicewonder. "VMAT2 Inhibitors for Tardive Dyskinesia—Practice Implications." Journal of Pharmacy Practice 32, no. 4 (2018): 450–57. http://dx.doi.org/10.1177/0897190018756512.

Full text

Abstract:

Tardive dyskinesia is a potentially irreversible, debilitating, hyperkinetic movement disorder that can result from dopamine receptor antagonists. Prompt recognition and resolution of symptoms are instrumental in preventing disease irreversibility, though current treatment options have fallen short of robust, effective, and long-term symptom control. In April 2017, the Food and Drug Administration (FDA) approved 2 new vesicular monoamine transporter 2 (VMAT2) inhibitors, deutetrabenazine and valbenazine, for chorea related to Huntington’s disease and tardive dyskinesia, respectively. These age

APA, Harvard, Vancouver, ISO, and other styles

4

Kazumori, Hideaki, Shunji Ishihara, Mohammad A. K. Rumi, Cesar F. Ortega-Cava, Yasunori Kadowaki та Yoshikazu Kinoshita. "Transforming growth factor-α directly augments histidine decarboxylase and vesicular monoamine transporter 2 production in rat enterochromaffin-like cells". American Journal of Physiology-Gastrointestinal and Liver Physiology 286, № 3 (2004): G508—G514. http://dx.doi.org/10.1152/ajpgi.00269.2003.

Full text

Abstract:

For the production and vesicle storage of histamine, Enterochromaffin-like (ECL) cells express histidine decarboxylase (HDC) and vesicular monoamine transporter 2 (VMAT2). Although HDC and VMAT2 show dynamic changes during gastric ulcer healing, the control system of their expression has not been fully investigated. In the present study, we investigated the effect of transforming growth factor-α (TGF-α) and proinflammatory cytokines on HDC and VMAT2 expression in rat ECL cells. Time course changes in the expression of TGF-α during the healing of acetic acid-induced ulcers were studied. EGF rec

APA, Harvard, Vancouver, ISO, and other styles

5

Wiley, Shereta, Wendy Cerenzia, Sylvie Stacy, Chirag Shah, Leslie Lundt, and Khody Farahmand. "Understanding the Evolving Continuing Medical Education Needs of Physicians Managing Patients with TD." CNS Spectrums 26, no. 2 (2021): 149. http://dx.doi.org/10.1017/s1092852920002369.

Full text

Abstract:

AbstractThis study sought to understand the evolving continuing medical education (CME) needs of physicians managing patients with tardive dyskinesia (TD). A case-based survey was developed, and later updated, to assess current practice, knowledge, and attitudes of neurologists and psychiatrists in the management of patients with TD. The original and updated survey were fielded in May 2018 and March 2020, respectively, to US-practicing psychiatrists and neurologists. Results were obtained from 213 psychiatrists and 187 neurologists in 2018 and from 125 psychiatrists and 128 neurologists in 202

APA, Harvard, Vancouver, ISO, and other styles

6

Meyer, Jonathan M., Ericha Franey, Leslie Lundt, et al. "Clinician-Reported Patient Awareness of Symptoms and Severity of Tardive Dyskinesia in Patients Prescribed VMAT2 Inhibitors." CNS Spectrums 26, no. 2 (2021): 151. http://dx.doi.org/10.1017/s1092852920002400.

Full text

Abstract:

AbstractObjectiveVesicular monoamine transporter 2 (VMAT2) inhibitors including valbenazine are first-line therapies for tardive dyskinesia (TD), a persistent movement disorder associated with antipsychotic exposure. This real-world study was performed to assess the association between patient awareness of TD symptoms and clinician-assessed symptom severity.MethodsClinicians who treated antipsychotic-induced TD with a VMAT2 inhibitor within the past 24 months were asked to extract demographic/clinical data from patients charts and complete a survey for additional data, including patient awaren

APA, Harvard, Vancouver, ISO, and other styles

7

Kimura, Shunsuke, Masahiro Sekiguchi, Kentaro Watanabe, et al. "Association of high-risk neuroblastoma classification based on expression profiles with differentiation and metabolism." PLOS ONE 16, no. 1 (2021): e0245526. http://dx.doi.org/10.1371/journal.pone.0245526.

Full text

Abstract:

Neuroblastoma, the most common extracranial solid malignancy among children, originates from undifferentiated neural crest cells (NCC). Despite recent intensified treatment, high-risk patients still have a high mortality rate. To explore a new therapeutic strategy, we performed an integrated genomic and transcriptomic analysis of 30 high-risk neuroblastoma cases. Based on the expression profiling of RNA sequencing, neuroblastoma was classified into Mesenchymal (MES; n = 5) and Noradrenergic (ADRN; n = 25) clusters, as previously reported in the super-enhancer landscape. The expression patterns

APA, Harvard, Vancouver, ISO, and other styles

8

Mojard Kalkhoran, Somayeh, Sarah Heather Jane Chow, Jagdeep Singh Walia, et al. "VNUT and VMAT2 segregate within sympathetic varicosities and localize near preferred Cav2 isoforms in the rat tail artery." American Journal of Physiology-Heart and Circulatory Physiology 316, no. 1 (2019): H89—H105. http://dx.doi.org/10.1152/ajpheart.00560.2018.

Full text

Abstract:

ATP and norepinephrine (NE) are coreleased from peripheral sympathetic nerve terminals. Whether they are stored in the same vesicles has been debated for decades. Preferential dependence of NE or ATP release on Ca2+ influx through specific voltage-gated Ca2+ channel (Cav2) isoforms suggests that NE and ATP are stored in separate vesicle pools, but simultaneous imaging of NE and ATP containing vesicles within single varicosities has not been reported. We conducted an immunohistochemical study of vesicular monoamine transporter 2 (VMAT2/SLC18A2) and vesicular nucleotide translocase (VNUT/SLC17A9

APA, Harvard, Vancouver, ISO, and other styles

9

Adam, Yoav, Robert H. Edwards, and Shimon Schuldiner. "Expression and function of the rat vesicular monoamine transporter 2." American Journal of Physiology-Cell Physiology 294, no. 4 (2008): C1004—C1011. http://dx.doi.org/10.1152/ajpcell.00348.2007.

Full text

Abstract:

The vesicular monoamine transporters (VMATs) are essential proteins, involved in the storage of monoamines in the central nervous system and in endocrine cells, in a process that involves exchange of 2H+with one substrate molecule. The VMATs interact with various native substrates and clinically relevant drugs and display the pharmacological profile of multidrug transporters. Vesicular transporters suffer from a lack of biochemical and structural data due to the difficulties in their expression. In this work we present the high-level expression of rat VMAT2 (rVMAT2) in a stable a human embryon

APA, Harvard, Vancouver, ISO, and other styles

10

Lin, Chih-Chun, and William G. Ondo. "Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia." Journal of the Neurological Sciences 389 (June 2018): 48–54. http://dx.doi.org/10.1016/j.jns.2018.02.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Vartak, Ashish P., A. Gabriela Deaciuc, Linda P. Dwoskin, and Peter A. Crooks. "Quinlobelane: A water-soluble lobelane analogue and inhibitor of VMAT2." Bioorganic & Medicinal Chemistry Letters 20, no. 12 (2010): 3584–87. http://dx.doi.org/10.1016/j.bmcl.2010.04.117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Frolova, Veronika S., Yulia O. Nikishina, Yuri B. Shmukler, and Denis A. Nikishin. "Serotonin Signaling in Mouse Preimplantation Development: Insights from Transcriptomic and Structural-Functional Analyses." International Journal of Molecular Sciences 25, no. 23 (2024): 12954. https://doi.org/10.3390/ijms252312954.

Full text

Abstract:

Serotonin (5-HT), a versatile signaling molecule, plays a variety of roles in both neurotransmission and tissue regulation. The influence of serotonin on early development was first studied in marine invertebrate embryos and has since been documented in a variety of vertebrate species, including mammals. The present study investigates the expression and functional activity of serotonin components in mouse embryos, focusing on key receptors and transporters. Transcriptomic analyses revealed that mRNA transcripts related to serotonin show marked expression during the oogenesis and preimplantatio

APA, Harvard, Vancouver, ISO, and other styles

13

Vartak, Ashish P., A. Gabriela Deaciuc, Linda P. Dwoskin, and Peter A. Crooks. "ChemInform Abstract: Quinlobelane: A Water-Soluble Lobelane Analogue and Inhibitor of VMAT2." ChemInform 41, no. 47 (2010): no. http://dx.doi.org/10.1002/chin.201047195.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Junichi, Kitanaka. "How the histamine N-methyltransferase inhibitor metoprine alleviates methamphetamine reward." Journal of Addiction Medicine and Therapeutic Science 3, no. 2 (2017): 016–23. https://doi.org/10.17352/2455-3484.000021.

Full text

Abstract:

Methamphetamine (METH) is a highly addictive psychomotor stimulant drug that is abused worldwide [1]. METH abuse results in numerous adverse effects after acute administration, as well as an array of adverse outcomes associated with binge use, long-term use, and withdrawal [2-4]. Acutely METH releases dopamine from synaptic terminals through multiple actions that include inducing reverse transport of dopamine via the dopamine transporter (DAT), impairing the function of the vesicular monoamine transporter-2 (VMAT2), leading to increased cytoplasmic dopamine concentrations, and inhibition of mo

APA, Harvard, Vancouver, ISO, and other styles

15

Dorotenko, A. R., I. M. Sukhanov, A. A. Savchenko, O. A. Dravolina, and I. V. Belozertseva. "Tolerance to paradoxical increase in motor activity caused by inhibition of phosphodiesterase 10a in a model of hypodopaminergy." Scientific Notes of the Pavlov University 30, no. 4 (2023): 32–42. http://dx.doi.org/10.24884/1607-4181-2023-30-4-32-42.

Full text

Abstract:

Introduction. Phosphodiesterases (PDEs) are a group of enzymes that hydrolyze the phosphodiester bond in cyclic nucleotides. PDE10A is mainly present in the medium-sized spiny neurons of the striatum. Functionally, PDE10A inhibition imitates the effect of D1-like agonists and D2-like dopamine receptor antagonists, and simultaneously modulating “direct” and “indirect” striato-thalamo-cortical brain pathway. To date, the effects of PDE10A inhibition have been characterized mainly, reproducing the inhibitory motor activity of D2-like dopamine receptor antagonists.The objective was to evaluate the

APA, Harvard, Vancouver, ISO, and other styles

16

Wilmouth, Carrie E., Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo. "Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats." Pharmacology Biochemistry and Behavior 112 (November 2013): 29–33. http://dx.doi.org/10.1016/j.pbb.2013.09.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Beckmann, Joshua S., Emily D. Denehy, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo. "The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats." Psychopharmacology 220, no. 2 (2011): 395–403. http://dx.doi.org/10.1007/s00213-011-2488-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Kitanaka, Junichi, Nobue Kitanaka, Takashi Kandori, et al. "Inhibitory effect of tetrabenazine, a VMAT2 inhibitor, on morphine-induced hyperlocomotion in mice without affecting expression levels of dopamine transporter." Proceedings for Annual Meeting of The Japanese Pharmacological Society 93 (2020): 1—P—026. http://dx.doi.org/10.1254/jpssuppl.93.0_1-p-026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Alvers, Kristin M., Joshua S. Beckmann, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo. "The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats." Psychopharmacology 224, no. 2 (2012): 255–62. http://dx.doi.org/10.1007/s00213-012-2748-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Mpekoulis, George, Vassilina Tsopela, Anna Chalari, et al. "Dengue Virus Replication Is Associated with Catecholamine Biosynthesis and Metabolism in Hepatocytes." Viruses 14, no. 3 (2022): 564. http://dx.doi.org/10.3390/v14030564.

Full text

Abstract:

Previously, the association between the catecholamine biosynthetic enzyme L-Dopa decarboxylase (DDC) and Dengue virus (DV) replication was demonstrated in liver cells and was found to be mediated at least by the interaction between DDC and phosphoinositide 3-kinase (PI3K). Here, we show that biogenic amines production and uptake impede DV replication in hepatocytes and monocytes, while the virus reduces catecholamine biosynthesis, metabolism, and transport. To examine how catecholamine biosynthesis/metabolism influences DV, first, we verified the role of DDC by altering DDC expression. DDC sil

APA, Harvard, Vancouver, ISO, and other styles

21

Caroff, Stanley N., Leslie Citrome, Jonathan Meyer, et al. "41 A Modified Delphi Consensus Approach to Clinical Guidelines for Tardive Dyskinesia." CNS Spectrums 24, no. 1 (2019): 197–98. http://dx.doi.org/10.1017/s1092852919000348.

Full text

Abstract:

AbstractObjectiveVesicular monoamine transporter 2 (VMAT2) inhibitors are the first class of drugs approved to treat tardive dyskinesia (TD). With the recent approval of these medications, a modified Delphi process was implemented to address the need for updated clinical guidelines for TD screening, diagnosis, and treatment.MethodsA Steering Committee of 11 TD experts met in a Nominal Group meeting format to discuss/prioritize questions to be addressed about TD and identify individuals to be invited to serve as Delphi survey panelists. Two survey rounds were conducted anonymously; responses we

APA, Harvard, Vancouver, ISO, and other styles

22

Yash, Pratap Shinde*, B. Shinde Sonal, and Maharudra Solankar Varsha. "TRANSVERSAL PATCH ON HUNTINGTONS DISEASES." World Journal of Pharmaceutical Science and Research 4, no. 2 (2025): 1210 1225. https://doi.org/10.5281/zenodo.15560901.

Full text

Abstract:

Huntington's disease (HD) is a progressive neurodegenerative disorder marked by motor impairment, cognitive decline, and psychiatric symptoms. Deutetrabenazine, a deuterated analog of tetrabenazine, is an FDA-approved medication that alleviates chorea in HD patients by inhibiting vesicular monoamine transporter 2 (VMAT2), which modulates dopamine levels in the brain. However, oral administration of Deutetrabenazine can result in variable drug absorption, fluctuating plasma concentrations, and gastrointestinal side effects, posing challenges for consistent management of symptoms. This study inv

APA, Harvard, Vancouver, ISO, and other styles

23

Li, Mingkai, Jing Hu, Zhong Chen, et al. "Evidence for histamine as a neurotransmitter in the cardiac sympathetic nervous system." American Journal of Physiology-Heart and Circulatory Physiology 291, no. 1 (2006): H45—H51. http://dx.doi.org/10.1152/ajpheart.00939.2005.

Full text

Abstract:

The colocalization of histamine (HA) and norepinephrine (NE) immunoreactivities was identified within the superior cervical ganglia neurons of the guinea pig. HA and NE immunoreactivity levels were significantly attenuated after chemical sympathectomy with 6-hydroxydopamine (6-OHDA). Coexistence of NE and HA was also visualized in the cardiac sympathetic axon and varicosities labeled with anterograde tracer biotinylated dextran amine. Depolarization of cardiac sympathetic nerve endings (synaptosomes) with 50 mM potassium stimulated endogenous HA release, which was significantly attenuated by 6

APA, Harvard, Vancouver, ISO, and other styles

24

Meyer, Jonathan M. "Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia." CNS Spectrums 21, S1 (2016): 13–24. http://dx.doi.org/10.1017/s1092852916000730.

Full text

Abstract:

The broad use of atypical antipsychotics was expected to dramatically reduce the prevalence and incidence of tardive dyskinesia (TD), but data show that TD remains an important challenge due the persistent nature of its symptoms and resistance to numerous treatment modalities, including antipsychotic discontinuation. Recent insights on genetic risk factors and new concepts surrounding pathophysiology have spurred interest in the possibility of targeted treatment for TD. As will be reviewed in this article, the number of evidence-based strategies for TD treatment is small: only clonazepam, aman

APA, Harvard, Vancouver, ISO, and other styles

25

Huang, Mei, Wenqi He, Lakshmi Rajagopal, Andrea Kudwa, Dimitri E. Grigoriadis, and Herbert Y. Meltzer. "Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action." Pharmacology Biochemistry and Behavior 190 (March 2020): 172872. http://dx.doi.org/10.1016/j.pbb.2020.172872.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Jankovic, Joseph, Barbara Coffey, Daniel O. Claassen, et al. "152 Development of Deutetrabenazine as a Potential New Non-Antipsychotic Treatment for Tourette Syndrome in Children and Adolescents." CNS Spectrums 25, no. 2 (2020): 297. http://dx.doi.org/10.1017/s1092852920000681.

Full text

Abstract:

Abstract:Background:Tourette syndrome (TS) is a neurodevelopmental disorder characterized by the hyperkinetic movements of motor and phonic tics manifested in young age. Currently approved treatments in the United States are antipsychotics: haloperidol, pimozide, and aripiprazole, which are associated with serious side effects, including tardive dyskinesia (TD). Deutetrabenazine, a vesicular monoamine transporter type 2 (VMAT2) inhibitor, was approved in 2017 by the US FDA for the treatment of chorea associated with Huntington’s disease and TD. Three ongoing studies (Alternatives for Reducing

APA, Harvard, Vancouver, ISO, and other styles

27

Wang, Yuwei, Pei Zhang, Yulin Chao, et al. "Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines." Cell Research 34, no. 1 (2024): 47–57. http://dx.doi.org/10.1038/s41422-023-00906-z.

Full text

Abstract:

AbstractMonoamine neurotransmitters such as serotonin and dopamine are loaded by vesicular monoamine transporter 2 (VMAT2) into synaptic vesicles for storage and subsequent release in neurons. Impaired VMAT2 function underlies various neuropsychiatric diseases. VMAT2 inhibitors reserpine and tetrabenazine are used to treat hypertension, movement disorders associated with Huntington’s Disease and Tardive Dyskinesia. Despite its physiological and pharmacological significance, the structural basis underlying VMAT2 substrate recognition and its inhibition by various inhibitors remains unknown. Her

APA, Harvard, Vancouver, ISO, and other styles

28

Jimenez-Shahed, Joohi, Hadas Barkay, Karen E. Anderson, et al. "Effect of Deutetrabenazine on Metabolic Parameters in the Treatment of Tardive Dyskinesia." CNS Spectrums 26, no. 2 (2021): 159–60. http://dx.doi.org/10.1017/s1092852920002564.

Full text

Abstract:

AbstractBackgroundDeutetrabenazine, a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, is approved by the FDA for treatment of tardive dyskinesia (TD) in adults. Dopamine-receptor antagonists (DRAs) are associated with worsening of metabolic parameters, including weight gain, hyperlipidemia, and elevated blood glucose. This post hoc analysis assessed the short- and long-term effects of deutetrabenazine treatment on weight and metabolic parameters in individuals treated for TD.MethodsTwo 12-week, randomized placebo-controlled trials (RCTs) of deutetrabenazine for patients with TD eval

APA, Harvard, Vancouver, ISO, and other styles

29

Tarakad, Arjun, and Joohi Jimenez-Shahed. "VMAT2 Inhibitors in Neuropsychiatric Disorders." CNS Drugs 32, no. 12 (2018): 1131–44. http://dx.doi.org/10.1007/s40263-018-0580-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Sreeram, Venkatesh, Shanila Shagufta, Faisal Kagadkar, and Mustafa Qureshi. "195 Current Use and Trends in the Management of Tardive Dyskinesia: Role of VMAT2 Inhibitors." CNS Spectrums 23, no. 1 (2018): 111. http://dx.doi.org/10.1017/s1092852918000743.

Full text

Abstract:

AbstractObjectivesTardive Dyskinesia (TD) is a debilitating condition that requires prompt care and intervention. Studies demonstrated the probable role of Vesicular Monoamine Transport 2 (VMAT2) in the pathogenesis of TD and use of VMAT2inhibitors in managing TD. Our aim is to provide available data on the management of TD and to determine the efficacy ofvarious VMAT2 inhibitors for independent use. Also, to identify their use in combination and assess if there, any change inoutcome with early intervention.MethodsWe did a pivotal search of the scientific literature by querying PubMed and Goog

APA, Harvard, Vancouver, ISO, and other styles

31

Vasireddy, Rani Priyanka, Brent Sokola, and Zain Guduru. "New generation VMAT2 inhibitors induced parkinsonism." Clinical Parkinsonism & Related Disorders 3 (2020): 100078. http://dx.doi.org/10.1016/j.prdoa.2020.100078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Niemann, Nicki, and Joseph Jankovic. "Real-World Experience With VMAT2 Inhibitors." Clinical Neuropharmacology 42, no. 2 (2019): 37–41. http://dx.doi.org/10.1097/wnf.0000000000000326.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Frank, Samuel, Claudia M. Testa, David Stamler, et al. "Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington’s Disease: Results From the ARC-HD Open-label Study." CNS Spectrums 26, no. 2 (2021): 164–65. http://dx.doi.org/10.1017/s1092852920002655.

Full text

Abstract:

AbstractBackgroundChorea is a prominent motor dysfunction in Huntington’s disease (HD). Deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, is FDA-approved for the treatment of chorea in HD. In the pivotal, 12-week First-HD trial, deutetrabenazine treatment reduced the Unified Huntington’s Disease Rating Scale (UHDRS) total maximal chorea (TMC) score versus placebo. ARC-HD, an open-label extension study, evaluated long-term safety and efficacy of deutetrabenazine dosed in a response-driven manner for treatment of HD chorea.MethodsPatients who completed First-HD (Rollover)

APA, Harvard, Vancouver, ISO, and other styles

34

Verghese, Cherian, Jean-Pierre Lindenmayer, Stephen R. Marder, et al. "38 Global Improvement and Patient Satisfaction: Results from a Long-term, Open-label, Rollover Study of Valbenazine in Tardive Dyskinesia." CNS Spectrums 24, no. 1 (2019): 195–96. http://dx.doi.org/10.1017/s1092852919000312.

Full text

Abstract:

AbstractObjectiveValbenazine (VBZ) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved to treat tardive dyskinesia (TD) in adults. It has been evaluated in 2 long-term studies (KINECT 3, KINECT 4) in which participants received VBZ (40 or 80mg) for up to 48weeks. This long-term rollover study (NCT02736955) was conducted to evaluate global TD improvement and patient satisfaction with once-daily VBZ.MethodsKey eligibility criteria: age 18 to 85 years; completion of KINECT 3 or KINECT 4; maintenance medications (for schizophrenia, schizoaffective disorder, or mood disorder) at

APA, Harvard, Vancouver, ISO, and other styles

35

Cutler, Andrew J., Rakesh Jain, Alon Bloom, Scott Siegert, and Leslie Lundt. "Treatment Success and Psychiatric Stability in Adults With Tardive Dyskinesia: Post Hoc Analyses of Two Long-Term Valbenazine Studies." CNS Spectrums 28, no. 2 (2023): 216–17. http://dx.doi.org/10.1017/s109285292300130x.

Full text

Abstract:

AbstractIntroductionTardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with exposure to antipsychotics and other dopamine receptor blocking agents. Effective and comprehensive treatment of TD requires reducing patients’ abnormal involuntary movements without disrupting their psychiatric stability. This can be especially challenging when patients have complex psychiatric conditions (e.g., >1 psychiatric diagnosis) and are taking multiple medications. Valbenazine, a highly potent and selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is

APA, Harvard, Vancouver, ISO, and other styles

36

Johnson, Kayla. "Clinical experience and treatment considerations with vesicular monoamine transport 2 inhibitors." Mental Health Clinician 14, no. 6 (2024): 304–12. https://doi.org/10.9740/mhc.2024.12.304.

Full text

Abstract:

Abstract Vesicular monoamine transporter 2 inhibitors (VMAT2i) are currently Food and Drug Administration–approved for the treatment of Huntington disease chorea and tardive dyskinesia. Additionally, they are often used for other hyperkinetic movement disorders in clinical practice. Due to a lack of head-to-head clinical trials, management of VMAT2i in the clinical setting may be unclear and rely on the clinical experience of the practitioner. Due to the limited distribution model, which typically requires VMAT2i to be dispensed by specialty pharmacies, access and initiation of treatment may p

APA, Harvard, Vancouver, ISO, and other styles

37

Bera, Rimal, Ericha Franey, Kendra Martello, Morgan Bron, and Chuck Yonan. "TeleSCOPE: A Real-World Study of Telehealth for the Detection and Treatment of Drug-Induced Movement Disorders." CNS Spectrums 27, no. 2 (2022): 250. http://dx.doi.org/10.1017/s109285292200061x.

Full text

Abstract:

AbstractIntroductionAs a result of COVID-19, patients and clinicians rapidly shifted to telehealth. An observational survey study, Real-World Tele-Health Evaluation of Tardive Dyskinesia (TD) Symptoms Communication/Observation Procedure Evaluation in Outpatient Clinical Settings (TeleSCOPE), was conducted to better understand how this shift affected the evaluation of drug-induced movement disorders (DIMDs), including TD.MethodsTwenty-minute online quantitative surveys were conducted with neurology and psychiatry specialists (physicians and advanced practice providers) who met the following cri

APA, Harvard, Vancouver, ISO, and other styles

38

Correll, Christoph U., Jean-Pierre Lindenmayer, Khody Farahmand, Eric Jen, Scott Siegert, and Eduardo Dunayevich. "Sustained Treatment Response With Long-Term Valbenazine in Patients With Tardive Dyskinesia." CNS Spectrums 28, no. 2 (2023): 240. http://dx.doi.org/10.1017/s1092852923001712.

Full text

Abstract:

AbstractBackgroundValbenazine is a once-daily VMAT2 inhibitor approved for the treatment of tardive dyskinesia (TD), a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotics, antiemetics, and other dopamine receptor blocking agents. The efficacy, safety, and tolerability of valbenazine has been established in several phase 3 trials, including a long-term study (KINECT 4 [NCT02405091]) in which participants received open-label valbenazine (40 or 80 mg) for 48 weeks. Post hoc analyses of KINECT 4 data were conducted to assess patterns of treat

APA, Harvard, Vancouver, ISO, and other styles

39

Mychaskiw, Marko, Julian Casciano, Zenobia Dotiwala, Nayla Chaijale, and Stacy Finkbeiner. "Real-World Antipsychotic and Vesicular Monoamine Transporter Type 2 Inhibitor Treatment Patterns in Patients Newly Diagnosed with Tardive Dyskinesia." CNS Spectrums 29, no. 5 (2024): 500–501. https://doi.org/10.1017/s1092852924001640.

Full text

Abstract:

IntroductionTardive dyskinesia (TD) is associated with antipsychotic (AP) use and management includes antipsychotic (AP) dose modification/discontinuation, often leaving underlying psychiatric conditions undertreated. Deutetrabenazine (DTBZ) is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) approved to treat TD and Huntington disease– associated chorea. AP and VMAT2i treatment patterns post-TD diagnosis are unclear.MethodsPatients aged ≥18 years, newly diagnosed with TD (July 2019– June 2022), with ≥1 AP and no VMAT2i claims pre-index were identified from the Symphony Health Solut

APA, Harvard, Vancouver, ISO, and other styles

40

Scorr, Laura M., and Stewart A. Factor. "VMAT2 inhibitors for the treatment of tardive dyskinesia." Journal of the Neurological Sciences 389 (June 2018): 43–47. http://dx.doi.org/10.1016/j.jns.2018.02.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Remington, Gary, Dao Thai-Cuarto, Joshua Burke, Scott Siegert, and Grace S. Liang. "132 Effects of Valbenazine on Depression and Suicidality in Adults With Tardive Dyskinesia: Pooled Results of 3 Double-Blind, Placebo-Controlled Trials." CNS Spectrums 23, no. 1 (2018): 82–83. http://dx.doi.org/10.1017/s1092852918000287.

Full text

Abstract:

AbstractStudy ObjectivesValbenazine (INGREZZA; VBZ) is a novel and highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor that is approved for the treatment of tardive dyskinesia (TD) in adults. The randomized, double-blind, placebo (PBO)-controlled trials of VBZ evaluated the treatment of TD in patients with a primary psychiatric diagnosis (schizophrenia/schizoaffective disorder or mood disorder) while on concomitant psychiatric medications to manage these disorders. Since treatment-emergent depression and suicidal ideation/behavior are important clinical concerns in psychiatric

APA, Harvard, Vancouver, ISO, and other styles

42

Lindenmayer, Jean-Pierre, Stephen R. Marder, Carlos Singer, et al. "77 Long-term Valbenazine Treatment in Patients with Schizophrenia/Schizoaffective Disorder or Mood Disorder and Tardive Dyskinesia." CNS Spectrums 24, no. 1 (2019): 214–15. http://dx.doi.org/10.1017/s1092852919000579.

Full text

Abstract:

AbstractBackgroundPatients treated with antipsychotics, regardless of psychiatric diagnosis, are at risk for developing tardive dyskinesia (TD), a potentially debilitating drug-induced movement disorder. Valbenazine (INGREZZA; VBZ) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved to treat TD in adults. Data from KINECT 4 (NCT02405091) were analyzed to evaluate the long-term effects of VBZ in adults with schizophrenia/schizoaffective disorder (SZD) or mood disorder (MD) and moderate or severe TD.MethodsKINECT 4 included open-label treatment (48weeks) followed by washout (

APA, Harvard, Vancouver, ISO, and other styles

43

Caroff, Stanley N., Jean-Pierre Lindenmayer, Stephen R. Marder, Stewart A. Factor, Khodayar Farahmand, and Leslie Lundt. "139 Early Response with Valbenazine and Long-Term Symptom Reduction in Patients with Tardive Dyskinesia: Post Hoc Analysis of the KINECT 3 Study." CNS Spectrums 25, no. 2 (2020): 288–89. http://dx.doi.org/10.1017/s1092852920000553.

Full text

Abstract:

Abstract:Study Objective:Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotics and other dopamine receptor blocking agents. Valbenazine is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of TD in adults. Using data from a long-term study (KINECT 3; NCT02274558), the effects of once-daily valbenazine (40 mg, 80 mg) on TD were assessed using the Abnormal Involuntary Movement Scale (AIMS) in participants who were early responders based on subjective measures, includ

APA, Harvard, Vancouver, ISO, and other styles

44

Maurel, Agnès, Odile Spreux-Varoquaux, Francesco Amenta, et al. "Vesicular monoamine transporter 1 mediates dopamine secretion in rat proximal tubular cells." American Journal of Physiology-Renal Physiology 292, no. 5 (2007): F1592—F1598. http://dx.doi.org/10.1152/ajprenal.00514.2006.

Full text

Abstract:

Renal dopamine, synthesized by proximal tubules, plays an important role in the regulation of renal sodium excretion. Although the renal dopaminergic system has been extensively investigated in both physiological and pathological situations, the mechanisms whereby dopamine is stored and secreted by proximal tubule cells remain obscure. In the present study we investigated whether vesicular monoamine transporters (VMAT)-1 and -2, which participate in amine storing and secretion, are expressed in rat renal proximal tubules, and we defined their involvement in dopamine secretion. By combining RT-

APA, Harvard, Vancouver, ISO, and other styles

45

Koch, Jessa, Wei-Xing Shi, and Khashayar Dashtipour. "VMAT2 inhibitors for the treatment of hyperkinetic movement disorders." Pharmacology & Therapeutics 212 (August 2020): 107580. http://dx.doi.org/10.1016/j.pharmthera.2020.107580.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Price, Lawrence H. "The VMAT2 inhibitors: New hope for an old scourge." Brown University Psychopharmacology Update 28, no. 11 (2017): 5. http://dx.doi.org/10.1002/pu.30274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Stahl, Stephen M. "Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects." CNS Spectrums 23, no. 1 (2017): 1–6. http://dx.doi.org/10.1017/s1092852917000621.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Kim, Anne P., Danial E. Baker, and Terri L. Levien. "VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia." Consultant Pharmacist 33, no. 4 (2018): 201–9. http://dx.doi.org/10.4140/tcp.n.2018.201.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Chepke, Craig, Stephen R. Marder, Cynthia L. Comella, Carlos Singer, Khodayar Farahmand, and Leslie Lundt. "123 Long-Term Outcomes with Valbenazine 40 mg/day in Adults With Tardive Dyskinesia." CNS Spectrums 25, no. 2 (2020): 279–80. http://dx.doi.org/10.1017/s1092852920000413.

Full text

Abstract:

Abstract:Study Objective:Tardive dyskinesia (TD), a persistent and potentially disabling movement disorder, is associated with prolonged exposure to antipsychotics and other dopamine receptor blocking agents. Valbenazine (VBZ) is a novel and highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of TD in adults. Using data from two long-term phase 3 studies (KINECT 3 [K3], NCT02274558; KINECT 4 [K4], NCT02405091) and a rollover study (1506, NCT02736955), the long-term outcomes of once-daily VBZ on TD were examined in participants who received 40mg or ha

APA, Harvard, Vancouver, ISO, and other styles

50

Marder, Stephen R., Cynthia L. Comella, Carlos Singer, Khodayar Farahmand, and Roland Jimenez. "140 Effects of Long-Term Valbenazine on Tardive Dyskinesia in KINECT 4: Post Hoc Response and Shift Analyses." CNS Spectrums 25, no. 2 (2020): 289. http://dx.doi.org/10.1017/s1092852920000565.

Full text

Abstract:

Abstract:Study Objective:Valbenazine (VBZ) is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia (TD), a persistent and potentially disabling movement disorder associated with prolonged antipsychotic exposure. Post hoc response and shift analyses were conducted using Abnormal Involuntary Movement Scale (AIMS) data from KINECT 4 (NCT02405091), a long-term open-label study in which participants received up to 48 weeks of open-label treatment with once-daily VBZ (40 or 80 mg).Methods:KINECT 4 included participants who met the fo

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!